This site is intended for UK healthcare professionals

 
Sponsorship statement:
Novartis Pharmaceuticals UK Ltd has provided OmniaMed Communications Ltd with an arm’s length sponsorship towards the development of the British Journal of Cardiology Masterclasses.
novartis-logo-transparent

Masterclass: Looking at lipids – dyslipidemia in CVD prevention

30 April 2024
Available for 1 CPD point(s)

Masterclass

Watch Terry McCormack and Peter Green discuss the national guidelines for primary and secondary prevention of cardiovascular disease (CVD), risk assessment and recommended lipid targets for CVD, and the availability of smart open-access data tools that can reduce health inequalities and improve treatment outcomes for your patients.
Speakers

Professor Terry McCormack Professor of Primary Care Cardiovascular Medicine, Hull York Medical School
Dr Peter Green GP, High Parks Medical Practice, University of Kent

Learning objectives

  • Understand the national guidelines for lipid management for primary and secondary prevention of CVD
  • Understand the lipid targets for prevention of CVD
  • Update knowledge on assessing cholesterol levels and understand why guidelines now include measurements for non-high-density lipoprotein cholesterol (non-HDL-C)
  • Understand the national guidelines for CVD risk assessment and follow up
  • Recognise the importance and use of smart open-access data tools CVDPREVENT and CVDACTION

Learning module instructions

This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning). Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value. After you have successfully completed the test you will be able to download your certificate.

References
  1. NHS England. Summary of national guidance for lipid management for primary and secondary prevention of CVD. 2022. Available from: https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2020/04/lipid-management-pathway-v6.pdf (accessed April 2024)
  2. Cardiovascular disease: risk assessment and reduction, including lipid modification [NG238]. 2023. Available from: https://www.nice.org.uk/guidance/ng238/resources/cardiovascular-disease-risk-assessment-and-reduction-including-lipid-modification-pdf-66143902851781 (accessed April 2024)
  3. Reynolds TM et al. Vasc Health Risk Manag 2021;17:227–37
  4. Guo L-L et al. Front Cardiovasc Med 2021;8:649181
  5. Liu M-M et al. Ann Transl Med 2021;9:386
  6. UCLPartners Health Innovation. CVDACTION: Transforming the prevention of cardiovascular disease. Available from: https://uclpartners.com/our-priorities/cardiovascular/cvdaction-transforming-the-prevention-of-cardiovascular-disease/ (accessed April 2024)
  7. Ma H, Shieh K-J. Am J Sci 2006;2:46–50
  8. Nelson RH. Prim Care 2013;40:195–211
  9. Taskinen MR, Borén J. Atherosclerosis 2015;239:483–95
  10. Chiesa ST et al. Eur Heart J 2019;40:3559–66
  11. Reiss AB et al. Am J Kidney Dis 2015;66:1071–82

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.